A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer
This study has been completed.
Jiangsu HengRui Medicine Co., Ltd.
Information provided by (Responsible Party):
Xichun Hu, Fudan University
First received: July 10, 2012
Last updated: December 1, 2013
Last verified: March 2013
The hypothesis of this clinical research study is to discover if the study drug Famitinib Malate can shrink or slow the growth of pretreated HER2-negative metastatic breast cancer.
Drug: Famitinib Malate
||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Single-Institutional, Phase II, Open-label, Single Arm Trial of Famitinib Malate in in HER2-negative Metastatic Breast Cancer
Primary Outcome Measures:
- ORR (Objective response rate) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- PFS(Progression free survival) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
- OS (Overall survival) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
- CBR(Clinical benefit rate) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
- QoL (Quality of life) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
- Number of adverse events [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||November 2013 (Final data collection date for primary outcome measure)
Experimental: Famitinib Malate
Drug: Famitinib Malate
The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
Famitinib Malate is a tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor 2(VEGFR2), and its anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the recommended phase II dose is 25 mg. The hypothesis of this clinical research study is to discover if the study drug Famitinib Malate can shrink or slow the growth of pretreated HER2-negative breast cancer. The safety of Famitinib Malate will also be studied. Patients physical state, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if Famitinib Malate is safe and effective in pretreated HER2-negative metastatic breast cancer patients.
|Ages Eligible for Study:
||18 Years to 70 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
●≥ 18 and ≤ 70 years of age.
- ECOG performance status of 0-1.
- Women diagnosed with HER2-negative breast cancer. HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH/CISH negative for gene amplification.
- Metastatic breast cancer, confirmed by histological analysis.
- Have failed from the last chemotherapy regimen, but experienced at most 2 regimens in the relapsed or metastatic setting. Pretreated anthracycline, taxanes and capecitabine (any rational reason for no use of capecitabine is acceptable) are mandatory.
- Have failed from at least 1 endocrine therapy, if HR positive.
- Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).
- Have at least one extracranial measurable site of disease according to RECIST 1.1 criteria that has not been previously irradiated.
- Life expectancy of more than 3 months.
- If the patients have brain or meninges metastases, the lesions must have been controlled at least 8 weeks.
- Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, neutrophils ≥ 1.5×10^9/L, platelets ≥ 80×10^9/L , ALT ≤ 2.5 x upper limit of normal (ULN), AST ≤ 2.5 x ULN, serum bilirubin ≤ 1.5 x ULN, serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min, PT, APTT ≤ 1.5 x ULN), serum cholesterol ≤ 1.25 x ULN, serum glycerin trilaurate ≤ 2.0 x ULN, LVEF ≥ lower limit of normal (LLN).
- Negative serum or urine pregnancy test taken in all women within 7 days before inclusion. Sexually active women of childbearing potential must use a medically acceptable form of contraception (which include oral contraception, injectable or implantable methods, intrauterine devices, or properly used barrier contraception) from the beginning of the study to 8 weeks after the last dose of the investigated drug. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
- Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time without prejudice.
- Pregnant or lactating women.
- Uncontrolled hypertension with mono-drug therapy (＞140/90 mm Hg)；ischemia of the myocardium （≥ grade 2） or myocardial infarction；arrhythmia（≥ grade 2, QTcF ＞ 480ms for female patients） or New York Heart Association Class III/IV.
- Abnormal thyroid function history with drug intervention.
- Any factors that influence the usage of oral administration.
- The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 300 mg/m2 and 600 mg/m2, respectively.
- Brain or meningeal metastases.
- Receiving the therapy of thrombolysis or anticoagulation.
- Unhealed wound or bone fracture.
- Urine protein ≥++ and confirmed ＞1.0 g by the 24h quantity.
- Previous or present history of pulmonary fibrosis,interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis or greatly-impaired pulmonary function.
- Disability of serious uncontrolled intercurrence infection.
- The active HBV or HCV infection or HBV DNA ≥10^4/ml.
- Acquired or inherent immunodeficiency； HIV infection； organ transplantation history.
- Abuse of alcohol or drugs.
- Have received prior treatment with a VEGFR TKI (Bevacizumab is permitted).
- History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01653574
|Fudan University Cancer Hospital
|Shanghai, Shanghai, China, 200032 |
Jiangsu HengRui Medicine Co., Ltd.
||Xi-Chun Hu, Doctor
||Fudan Univeristy Cancer Hospital
No publications provided
||Xichun Hu, Deputy director of department of medical oncology, Fudan University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 10, 2012
||December 1, 2013
||China: Food and Drug Administration
Keywords provided by Fudan University:
Metastatic Breast Cancer
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 09, 2014
Neoplasms by Site